MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA (MPM) explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA (MPM) trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA (MPM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
Scientists map immune cells in rare cancer to boost treatment
Knowledge-focused Recruiting nowThis study looks at the immune system inside malignant pleural mesothelioma, a rare and hard-to-treat cancer. Researchers will analyze tumor samples from 300 adults to understand why immunotherapy helps only some patients. The goal is to find clues that could make these treatment…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC